scholarly journals Feasibility Study of a Proton Irradiation Facility for Radiobiological Measurements at an 18 MeV Cyclotron

Instruments ◽  
2018 ◽  
Vol 2 (4) ◽  
pp. 26 ◽  
Author(s):  
Anna Baratto-Roldán ◽  
María Jiménez-Ramos ◽  
Maria Battaglia ◽  
Javier García-López ◽  
María Gallardo ◽  
...  

A feasibility study of an experimental setup for the irradiation of biological samples at the cyclotron facility installed at the National Centre of Accelerators (Seville, Spain) is presented. This cyclotron, which counts on an external beam line for interdisciplinary research purposes, produces an 18 MeV proton beam, which is suitable for the irradiation of mono-layer cultures for the measurement of proton cell damages and Relative Biological Effectiveness (RBE) at energies below the beam nominal value. Measurements of this kind are of interest for proton therapy, since the variation of proton RBE at the distal edge of the Bragg curve may have implications in clinical proton therapy treatments. In the following, the characteristics of the beam line and the solutions implemented for the irradiation of biological samples are described. When dealing with the irradiation of cell cultures, low beam intensities and broad homogeneous irradiation fields are required, in order to assure that all the cells receive the same dose with a suitable dose rate. At the cyclotron, these constraints have been achieved by completely defocusing the beam, intercepting the beam path with tungsten scattering foils and varying the exit-window-to-sample distance. The properties of the proton beam thus obtained have been analysed and compared with Monte Carlo simulations. The results of this comparison, as well as the experimental measurement of the lateral dose profiles expected at the position of samples are presented. Meaningful dose rates of about 2–3 Gy/min have been obtained. Homogeneous lateral dose profiles, with maximum deviations of 5%, have been measured at a distance of approximately 50 cm in air from the exit window, placing a tungsten scattering foil of 200 μm in the beam path.

2021 ◽  
Author(s):  
Konrad P. Nesteruk ◽  
Michele Togno ◽  
Martin Grossmann ◽  
Anthony J. Lomax ◽  
Damien C. Weber ◽  
...  

2017 ◽  
Vol 44 (4) ◽  
pp. 1268-1274 ◽  
Author(s):  
Takeshi Arimura ◽  
Takashi Ogino ◽  
Takashi Yoshiura ◽  
Mitsugi Matsuyama ◽  
Naoaki Kondo ◽  
...  

1993 ◽  
Vol 40 (4) ◽  
pp. 1041-1044 ◽  
Author(s):  
A.M.J. Paans ◽  
J.M. Schippers

Author(s):  
Min Gao ◽  
Chien-Min Kao ◽  
Hsien-Hsin Chen ◽  
Xudong Lyu ◽  
Ji-Hong Hong ◽  
...  

1995 ◽  
Vol 32 (4) ◽  
pp. 1177-1183 ◽  
Author(s):  
Catherine Nauraye ◽  
Alejandro Mazal ◽  
Sabine Delacroix ◽  
André Bridier ◽  
Jean Chavaudra ◽  
...  

2019 ◽  
Vol 37 (30) ◽  
pp. 2778-2785 ◽  
Author(s):  
Rachel B. Jimenez ◽  
Shea Hickey ◽  
Nicolas DePauw ◽  
Beow Y. Yeap ◽  
Estelle Batin ◽  
...  

PURPOSE To evaluate the safety and efficacy of proton beam radiation therapy (RT) for patients with breast cancer who require regional nodal irradiation. METHODS Patients with nonmetastatic breast cancer who required postoperative RT to the breast/chest wall and regional lymphatics and who were considered suboptimal candidates for conventional RT were eligible. The primary end point was the incidence of grade 3 or higher radiation pneumonitis (RP) or any grade 4 toxicity within 3 months of RT. Secondary end points were 5-year locoregional failure, overall survival, and acute and late toxicities per Common Terminology Criteria for Adverse Events (version 4.0). Strain echocardiography and cardiac biomarkers were obtained before and after RT to assess early cardiac changes. RESULTS Seventy patients completed RT between 2011 and 2016. Median follow-up was 55 months (range, 17 to 82 months). Of 69 evaluable patients, median age was 45 years (range, 24 to 70 years). Sixty-three patients (91%) had left-sided breast cancer, two had bilateral breast cancer, and five had right-sided breast cancer. Sixty-five (94%) had stage II to III breast cancer. Sixty-eight (99%) received systemic chemotherapy. Fifty (72%) underwent immediate reconstruction. Median dose to the chest wall/breast was 49.7 Gy (relative biological effectiveness) and to the internal mammary nodes, 48.8 Gy (relative biological effectiveness), which indicates comprehensive coverage. Among 62 surviving patients, the 5-year rates for locoregional failure and overall survival were 1.5% and 91%, respectively. One patient developed grade 2 RP, and none developed grade 3 RP. No grade 4 toxicities occurred. The unplanned surgical re-intervention rate at 5 years was 33%. No significant changes in echocardiography or cardiac biomarkers after RT were found. CONCLUSION Proton beam RT for breast cancer has low toxicity rates and similar rates of disease control compared with historical data of conventional RT. No early cardiac changes were observed, which paves the way for randomized studies to compare proton beam RT with standard RT.


2020 ◽  
Author(s):  
Christian Hahn ◽  
Jan Eulitz ◽  
Nils Peters ◽  
Patrick Wohlfahrt ◽  
Wolfgang Enghardt ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document